7
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T21503 | (E/Z)-Zotiraciclib | (E/Z)-TG02,(E/Z)-SB1317 | FLT , JAK , CDK |
(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively. | |||
T2653 | SB1317 | TG02 | FLT , JAK , CDK |
SB1317 (TG02) is a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3). | |||
T70895 | H 35-25 | ||
H 35-25 is a beta 2-antagonist. | |||
T4227 | SB1317 hydrochloride (1204918-72-8(free base)) | TG-02 hydrochloride | FLT , JAK , CDK |
SB1317 hydrochloride (1204918-72-8(free base)) (TG-02 hydrochloride) is an effective inhibitor of CDK2/JAK2/FLT3 (IC50: 13/73/56 nM). | |||
T62056 | (E/Z)-Zotiraciclib hydrochloride | ||
(E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent inhibitor of CDK2, JAK2, and FLT3. | |||
T63998 | (E/Z)-Zotiraciclib citrate | ||
(E/Z)-Zotiraciclib ((E/Z)-TG02) citrate is a potent inhibitor of CDK2, JAK2 and FLT3 and can be used in cancer research. | |||
T70897 | Zotiraciclib HCl | ||
Zotiraciclib, also known as TG02 and SB1317, is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Zotiraciclib may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting M... |